Outcomes of correction of metabolic risk at a polycystic ovary syndrome after the metformin treatment
https://doi.org/10.14341/brh2011235-41
Abstract
Polycystic ovary syndrome (PCOS) – a polymorphic disease with extremely variable clinical presentation and different phenotypes found in 5-10% of women of reproductive age. During the life of women with PCOS in 10-fold increased risk of developing type 2 diabetes, 7 times – hypertension and coronary heart disease, including myocardial infarction, more than2-fold increased risk of developing ovarian cancer, endometrial, breast cancer. Women with PCOS and if they have insulin resistance, central obesity, dyslipidemia, have the greatest risk of developing diabetes and cardiovascular disease. The use of metformin is potentially an effective method to overcome insulin resistance, improve hormonal, biochemical parameters and a possible reduction in cardiovascular risk in PCOS.
About the Authors
E N Andreeva
Federal Endocrinological Research Center, Moscow, Russia
E V Sheremeteva
Federal Endocrinological Research Center, Moscow, Russia
I I Dedov
Federal Endocrinological Research Center, Moscow, Russia
References
1. Карпова Е.А., Андреева Е.Н. Применение метформина при синдроме поликистозных яичников. Трудный пациент. 2006; 9.
2. ACE Guidelines for Glycemic Control. AACE Position Statement on Insulin Resistance Syndrome. Endocrin Practice 2003; 9(suppl. 1):7-19.
3. Balkau B, Charles MA. For the European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16:442-43.
4. Bloomgarden ZT. Conference Report «Highlights From The First World Congress on the Insulin Resistance Syndrome (November 21-22, 2003; Los Angeles, California)». Medscape Diabetes & Endocrinology. 2004; 6:1 http://www.medscape.com/viewarticle/467200.
5. Barbieri RL, Hornstein MD. Hyperinsulinemia and ovarian hyperandrogenism: cause and effect. Endocrinol Metab Clin North. Am. 1988; I7: 685-97.
6. Caro F. Insulin resistance in obese and nonobese man. Clin Endocrinol Metab 1991; 73: 691-5.
7. Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubation of human ovarian stroma and theca. Obstet Gyn 1984; 64: 73-80.
8. Шостак Н.А., Аничков Д.А. К вопросу о диагностических критериях метаболического синдром. РМЖ. 2002; 27 (171): 1255-7.
9. Hopkinson ZEC, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 1998; 317: 329-32.
10. McKeigue P. Cardiovascular disease and diabetes in women with polycystic ovary syndrome. Balliere's Clin Endocrinol Metab 1996; 10:311-18.
11. Balen A. Metformin therapy for the management of infertility in women with polycystic ovary syndrome (PDF). Scientific Advisory Committee Opinion Paper 13. Royal College of Obstetricians and Gynaecologists (December 2008).
12. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. «Consensus on infertility treatment related to polycystic ovary syndrome». Hum Reprod 2008; 23 (3): 462-77.
13. Чазова И.Е., Мычка В.Б. Метаболический синдром. Кардиоваскулярная терапия и профилактика. 2003; 3: 32-8.
14. Шубина А.Т., Демидова И.Ю., Чернова Н.А., Карпов Ю.А. Метаболический синдром: возможности применения метформина. РМЖ. 2001; 9(2): 77-81.
15. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Prevention Program Research Group. Diabetes Care. 2003; 26 (4): 977-80.
16. Kendall D, Riddle M, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-91.
17. Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome (Cochrane Review). The Cochrane Library 2003. Issue 4. (ISSN 1464780X). Cochrane Database Syst Rev 2003; 3:CD003053.
18. Nardo LG, Buckett WM, Khullar V. Determination of the best fiting ultrasound formulaic method for ovarian volume measurement in women with polycystic ovary syndrome. Fertil Steril 2003; 79:632-33.
19. Genuth S, Brownlee MA, Kuller LH et al. Американская Диабетологическая Ассоциация. Консенсус конференции по инсулинорезистентности 5-6 ноября 1997 г. Междун мед журн. 2001; 1. http://medi.ru/doc/77.htm.
Review
For citations:
Andreeva E.N., Sheremeteva E.V., Dedov I.I. Outcomes of correction of metabolic risk at a polycystic ovary syndrome after the metformin treatment. Bulletin of Reproductive Health. 2011;(2):35-41. (In Russ.) https://doi.org/10.14341/brh2011235-41
Views:
514
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
